<DOC>
	<DOCNO>NCT00443443</DOCNO>
	<brief_summary>This observational study design follow patient RA inadequate response one anti-TNF therapy receive Rituxan . Approximately 1000 patient United States RA inadequate response anti-TNF therapy receive Rituxan therapy recruit . There protocol mandate treatment assignment study . Patients evaluate treated accord physician 's standard practice discretion .</brief_summary>
	<brief_title>A Study Safety Rituxan Patients With Rheumatoid Arthritis After Inadequate Response Previous Anti-TNF Therapy ( SUNSTONE )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>No prior use Rituxan ( except receive within 8 week screen ) Signed Informed Consent Form Age â‰¥ 18 year Diagnosis RA Inadequate response one antiTNF therapy Have know hypersensitivity component humanize murine monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>RA</keyword>
	<keyword>Sunstone</keyword>
	<keyword>anti-TNF</keyword>
	<keyword>Rituxan</keyword>
</DOC>